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Background: Urinary tract infections (UTI) are the most frequent bacterial infection affecting women and account
for about 15% of antibiotics prescribed in primary care. However, some women with a UTI are not prescribed
antibiotics or are prescribed the wrong antibiotics, while many women who do not have a microbiologically
confirmed UTI are prescribed antibiotics. Inappropriate antibiotic prescribing unnecessarily increases the risk of
side effects and the development of antibiotic resistance, and wastes resources.
POETIC is a randomised controlled trial of a Point Of Care Test (POCT) (Flexicult™) guided UTI management strategy
for use in primary care, which may help General Practitioners more effectively decide both whether or not to
prescribe antibiotics, and if so, to select the most appropriate antibiotic.
Methods/design: 614 adult female patients will be recruited from four primary care research networks (Wales,
England, Spain, the Netherlands) and individually randomised to either POCT guided care or the guideline-informed
‘standard care’ arm. Urine and stool samples (where possible) will be obtained at presentation (day 1) and two
weeks later for microbiological analysis. All participants will be followed up on the course of their illness and their
quality of life, using a 2 week self-completed symptom diary. At 3 months, a primary care notes review will be
conducted for evidence of further evidence of treatment failures, recurrence, complications, hospitalisations and
health service costs.
The primary objective is to compare appropriate antibiotic use on day 3 between the POCT and standard care arms
using multi-level logistic regression to produce an odds ratio and associated 95% confidence interval. Costs of the
two management approaches will be assessed in terms of the primary outcome.
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Discussion: Although the Flexicult™ POCT is used in some countries in routine primary care, it’s clinical and cost
effectiveness has never been evaluated in a randomised clinical trial. If shown to be effective, the use of this POCT
could benefit individual sufferers and provide evidence for health care authorities to develop evidence based
policies to combat the spread and impact of the unprecedented rise of infections caused by antibiotic resistant
bacteria in Europe.
Trial registration number: ISRCTN65200697 (Registered 10 September 2013).
Keywords: Urinary Tract Infection, Primary care, Adult women, Point-of-care-test, Near-patient testing, Antibiotic
resistance, Cost effectivenessBackground
Each year, about 10% of adult women experience a
urinary tract infection (UTI) and about 60% experience
a UTI at some point in their lives [1,2]. Recurrences are
common, with nearly half going on to experience a
subsequent UTI within a year. UTI accounts for about
15% of antibiotics prescribed in primary care, and be-
tween 34% and 60% of patients treated with an antibiotic
do not have a microbiologically proven UTI and 25% of
those with a positive urine culture are not prescribed
antibiotics.
For those who are likely to benefit, antibiotics have
been shown to reduce symptom duration [3]. However,
some do not benefit from antibiotics and as these carry
risks of side effects, increased antibiotic resistance and
costs, unnecessary antibiotic use should be minimised.
In a systematic review and meta-analysis of five studies
of urinary tract bacteria that included 14 348 partici-
pants, the pooled odds ratio (OR) for resistance was 2.5
(95% CI 2.1 to 2.9) within two months of antibiotic treat-
ment and 1.33 (95 % CI 1.2 to 1.5) within 12 months [4].
Antibiotic resistant UTIs are common in primary care,
with recent antibiotics the greatest single risk factor for
a resistant compared to a sensitive infection [5]. Resist-
ant infections are associated with longer illness duration,
increased re-consultations, and increased health care
costs [6,7].
Current strategies to predict bacteriological UTI in adult
women need refining so that more women who will bene-
fit from antibiotic treatment are prescribed them, anti-
biotic treatments are better targeted to the sensitivity of
the infecting organisms, and antibiotics are prescribed less
often for women who will not benefit. There is thus an
urgent need to support General Practitioners in deciding
both whether or not to prescribe antibiotics and, if so in
selecting the most appropriate antibiotic. Accurate diag-
nosis and rational treatment is required to minimise acute
suffering and help prevent recurrences.
The POETIC trial is an evaluation of a Point of Care
Test (POCT) guided UTI management strategy for use
in adult women presenting in primary care with suspected
uncomplicated UTI. The POCT that will be evaluated iscalled Flexicult™ and is a simple point of care culture pro-
cedure, and provides clinicians, at the point of care, within
24 hours, with a microbiological diagnosis of bacterial
UTI by quantifying bacteria in the urine sample (or not)
and determining sensitivities of any identified pathogen to
the antibiotics most commonly used for UTI in primary
care [8].
POETIC aims to determine the clinical effects and
costs of this optimised POCT guided diagnostic and
treatment strategy for symptoms of uncomplicated UTI
on the overall appropriateness of antibiotic prescribing
when compared to a “practice based on best available
local guidelines” strategy. The POETIC trial will deter-
mine whether or not the POCT aids clinicians to more
appropriately prescribe antibiotics for uncomplicated UTI’s
i.e. minimise the use of antibiotics for women where no
bacterial infection is identified, and ensure the narrowest
spectrum antibiotic appropriate to the sensitivity of the
infecting organisms is prescribed when a bacterial infec-
tion is identified, and whether or not the strategy is cost
effective.Methods/design
Trial design
POETIC is a two-arm, individual patient randomised con-
trolled trial aiming to quantify the effects and costs of an
optimised POCT guided diagnostic and treatment strategy
for symptoms of uncomplicated UTI on the overall appro-
priateness of antibiotic prescribing when compared to a
“practice based on best available local guidelines” strategy.
The research will be implemented in primary care research
networks in the four participating European countries
(Wales, England, the Netherlands and Spain).
The trial will randomise 614 eligible women to either
the POCT guided management strategy, or to a standard
UTI management strategy based on best local guidelines.Setting
This multinational trial will be implemented in primary
care research networks based in Wales, England, Spain
and the Netherlands. Each centre will recruit adult women
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18 years, from their affiliated primary care sites.
Trial intervention
Participants randomised to the experimental inter-
vention arm will have their treatment guided by the
Flexicult™ POCT. This POCT is a point of care culture-
based approach and involves fresh urine being placed on a
special agar plate and the excess urine poured off. The
plate is then placed in a simple desktop incubator within
the practice, and read approximately 24 hours later.
Patients can only be included in the POCT arm if the
clinician/nurse is able to read the plate 24 hours later.
The plate is divided into six segments. The largest com-
partment contains culture medium alone, and the other
five segments contain culture medium with impregnated
with different antibiotics with specific concentrations
commonly used for treating UTI in primary care. This
allows for assessment of bacterial growth (quantification),
evaluation of the species present, and assessment of resist-
ance to the antibiotics in each of the plate segments.
The Flexicult™ system has been used in primary care
settings in Denmark for approximately 10 years. POETIC
will use new Flexicult™ plates that have been developed by
the manufacturer and CE marked (Statens Serum Institut,
SSI) to include the antibiotics that are most commonly
used in the three participating regions (UK -England and
Wales, Spain and the Netherlands) (see Table 1 below):
Clinicians will be provided with training in the manage-
ment of UTI using the Flexicult™ approach. Two treatment
approaches will be available to participating clinicians for
patients randomised to this arm:
1) Provide patients with advice about symptomatic
management of their UTI for approximately
24 hours and arrange a mechanism for contacting
the patient in approximately 24 hours in order to
arrange provision of a prescription for antibiotics,
or not, as appropriate, based on the results of the
Flexicult™ POCT test.
2) Provide patients with a prescription for antibiotics to
start immediately and arrange a mechanism for
contacting the patient approximately 24 hours later
in order to advise the patient to continue taking theTable 1 Antibiotics included in Flexicult™ plate for each
region
UK Netherlands Spain
Trimethoprim Trimethoprim Fosfomycin
Nitrofurantoin Nitrofurantoin Nitrofurantoin
Amoxicillin/clavulanate Amoxicillin/clavulanate Amoxicillin/clavulanate
Ciprofloxacin Ciprofloxacin Ciprofloxacin
Cephalexin Amoxicillin Cefuroximeantibiotics, stop taking the antibiotics, or switch to
an alternative antibiotic, as appropriate, based on the
results of the Flexicult test.
Clinicians will be encouraged to adopt the first approach
for patients with milder symptoms and/or for those that
would be happy/would prefer to wait 24 hours for a more
definitive diagnosis, and the latter approach for those with
more severe symptoms or who are not happy to delay ini-
tiation of antibiotics.
Control arm –standard care
Patients randomised to the control arm will receive stand-
ard care informed by national guidelines. Clinicians will
receive a summary of national guidelines on the manage-
ment of uncomplicated UTI in primary care (UK, Spain
and the Netherlands). Participating clinicians will be pro-
vided with the relevant summary for their country, and
training in best practice based on their national guidelines.
The management of patients who are randomised to the
standard care arm will therefore be based upon the man-
agement decisions of clinicians who have received training
in best practice and a summary of their national guideline
(s). Management decisions in these patients randomised
to guideline informed usual care will not be guided by
the POCT.
Primary objective
The primary outcome will be appropriate antibiotic use
on day 3 (with day 1 being the day that the patient con-
sulted with their primary care clinician). For women
who are shown to have a UTI. Appropriate antibiotic
use on day 3 will be defined as use of an antibiotic for
which the isolated pathogen has been shown to have
in vitro sensitivity (based on laboratory analysis). For
women who do not have a UTI, appropriate antibiotic
use on day 3 will be defined as no antibiotic use on this
day. In the UK the definition of a UTI is defined for the
POETIC trial as ≥105 colony forming units per millilitre
(cfu/ml) of a pure/predominant recognised uropathogen,
however the varying definitions across the countries will
be considered.
Secondary objectives
The secondary objectives are to compare intervention
arms with regard to:
 Antibiotic choice in relation to presence of infection
and organism susceptibility and antibiotic spectrum
 Dose and duration of antibiotic prescribed
 Proportion of patients receiving antibiotic
prescription
 Adherence to national prescribing guidelines
 Symptoms/recovery
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 Patient satisfaction with management
 Antibiotic resistance in urine and stool samples
at two week follow up
 Direct/indirect costs
 Cost effectiveness
Ethical and governance approval
This trial protocol was approved by the Research Ethics
Committee (REC) For Wales recognised by the United
Kingdom Ethics Committee Authority (UKECA) and also
approved by the relevant local Governance Committees in
the Netherlands and Spain.
All sites within the UK received Research & Develop-
ment approval from the appropriate Health Boards and
Trusts before commencing trial. For Spain, approval was
obtained by the Institut d‘Investigació d’Atenció Primària
Jordi Gol i Gurina, Barcelona. For the Netherlands,
approval was obtained from Medisch Ethische Toetsings-
commissie of the Universitair Medisch Centrum Utrecht
(University Medical Center Utrecht).
Trial procedures
Primary care sites/GP practice recruitment
The trial centres have been selected on the basis of having
well-established primary care research networks and
representing contrasting European cultures and healthcare
systems. Each centre will recruit around 10 general prac-
tices to participate in the trial. Practices will be selected
on the basis of recruitment potential, with larger practices
and practices which have previous experience in recruiting
participants during routine consultations.
All participating practices will receive face-to-face
training with additional online resources, via a bespoke
POETIC website (www.POETIC-study.co.uk), in use of
the POCT strategy. This will include sample collection
and preparation, use of the POCT, interpretation of the
POCT results, data collection and storage, health and
safety issues and management strategies (how to use the
results of the POCT in line with best evidence and local
guidelines).
Microbiology laboratory recruitment
The participation of any primary care site in recruitment
to the trial requires the support and participation of a
research microbiology laboratory in each of the partici-
pating countries, to which the site sends urine and stool
samples for the purposes of the POETIC trial.
For sites in Wales and England, samples will be sent to
the Specialist Antimicrobial Chemotherapy Unit (SACU),
Public Health Wales Microbiology Cardiff, at University
Hospital of Wales. In The Netherlands, samples will
be sent to the Department of Medical Microbiology of
the Universitair Medisch Centrum Utrecht. In Spain,the samples will be sent to the Microbiological Depart-
ments of the Hospitals Ramón y Cajal (Madrid), Joan
XXIII (Tarragona), and Bon Pastor (Barcelona). All labo-
ratories will be provided with a POETIC microbiology
manual and standard operating procedures.
Participant recruitment
The recruitment process is summarised in Figure 1.
Registration and consent
Participating clinicians (GPs or nurse prescriber) will iden-
tify eligible patients during routine general practice consul-
tations. The participating clinician will assess eligibility,
provide potential participants with a verbal description of
the trial, and if the patient is interested, will provide them
with a comprehensive participant information leaflet (PIL).
All potential participants will be given sufficient time to
read the PIL, ask questions, and consider participation
before being asked to provide informed consent. Women
who consent to take part will be asked to sign a consent
form, which will also be signed by the clinician who is tak-
ing consent. Copies of the consent form will be kept in the
site file, and sent securely to the trial team in each centre.
All participating practices will be asked to keep an
anonymous screening log of all ineligible and eligible but
not consented/not approached patients. These will be
used to detect any selection bias.
Participants will be informed that they have the right
to withdraw consent for participation in the POETIC
trial at any time and that their clinical care will not be
affected at any time by declining to participate or with-
drawing from the trial.
Inclusion criteria
Women aged 18 years and older presenting to primary
care with at least one of three key urinary tract symptoms
(dysuria, urgency including nocturnal and frequency that
have been present for up to 14 days) and where the clin-
ician suspects uncomplicated UTI will be eligible to take
part. Patients should be able to provide written informed
consent and be willing to complete the patient diary.
Exclusion criteria
Women with one or more of the following will not
eligible for inclusion:
 Terminally ill
 Currently receiving treatment for life-threatening
cancer (basal cell carcinoma, for example, excluded)
 Other severe systemic symptoms, such as high fever,
renal angle pain, rigors.
 On long-term antibiotic treatment or have received
antibiotics for urinary tract infection within the past
four weeks
Figure 1 Trial schema and participant flow diagram. Figure 1 provides an overview of the POETIC trial and participant flow process.
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within the past four weeks
 Known or likely to have significant immune
compromise (i.e. known immunodeficiency state,
on long-term corticosteroid or chemotherapy
treatment, insulin dependent diabetes)
 Known functional or anatomical abnormalities of
the genitourinary tract
 History of pyelonephritis Known pregnancy
 Unable to provide a urine sample on the day of first
presentation
The clinician will need to ensure the participant
provides a mid-stream urine (MSU) sample before leaving
the practice. Patients can only be included in the
POCT arm if the clinician is present to read the plate
24 hours later.
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A urine (required for participation) and stool (if possible)
sample will be collected from the participant on day 1
(day of recruitment) and at day 14 and analysed in the
research laboratories for presence of bacteria and any re-
sistance profiles. Patients who do not wish to provide stool
samples but are happy to participate in all other aspects of
the trial will be eligible for recruitment, as the stool
samples are not necessary for answering the primary aim
of the trial.
Participants will be provided with written instructions
on how to collect the urine and stool samples. Urine sam-
ples will be collected using a mid-stream urine collection
kit (Peezy MSU collection kit) to ensure a clean catch.
Stool samples will be collected using an ‘Easy sampler’ kit.
Participants will be asked to return samples to the labora-
tory within 24 hours of collection.
If the clinician requires a urine sample to be sent as
part of their clinical management, and there is insuffi-
cient urine for both clinical and research samples, the
clinical sample will take priority.
Urine samples, from both trial arms, will be trans-
ferred to a container containing boric acid for transport
to the research laboratory, to arrive at the laboratory
within 24 hours for identification and testing of anti-
microbial resistance. Results from the research micro-
biology laboratories will not routinely be disclosed to
participating clinicians or patients in either trial arm,
but will be available upon request in case of clinical
deterioration.
Data collection
Baseline case report form (CRF) – all participants
Eligibility An eligibility CRF will be completed for all
consented participants to ensure that they meet the
eligibility criteria set out in the protocol. The clinician
will then sign the form to confirm eligibility.
Randomisation The randomisation and allocation of
eligible participants will be undertaken as part of the
data collection process. Whilst completing the baseline
CRF, clinicians will be asked to randomise the patient
using a password protected POETIC randomisation web-
site. Each practice will be allocated unique login details to
the website. The clinician will enter the relevant data into
the website, including the required stratifying and balan-
cing variables, which include centre and practice details,
and number of presenting symptoms (dysuria, frequency,
urgency). The patient must present with at least one of
these in order to be eligible for the trial. Once all relevant
data has been entered, the randomisation programme will
provide the trial allocation for that participant (either
Standard care or POCT arm). This information will be
recorded on the baseline CRF.There is no credible blinding mechanism that can be
utilised in this trial. Immediately after receiving the allo-
cation, the clinician will need to be aware of the result
of the randomisation so as to know whether to use the
point of care test or not, and the participant will be need
to made aware as they may need to receive a new pre-
scription 24 hours after initial diagnosis, once the POCT
results are made available to the clinician.
Clinical examination
Following randomisation, participating clinicians will be
asked to record details of the patient’s presenting clinical
features (signs and symptoms) using a scale of 0-6 for each
feature. This CRF also asks the clinician to record: the use
of any diagnostic tests (i.e. urine dipstick testing), their
antibiotic management for the suspected UTI (including
name, dose, and duration of any medication prescribed), as
well as any other medication which is either prescribed or
advised. The CRF also records if any follow up appoint-
ments have been made and if the patient has taken any
time off paid employment due to their symptoms.
POCT (flexicult) test result CRF – POCT arm participants only
For patients randomised to the POCT strategy, the result
of the test should be available 24 hours after inoculation
with a urine sample at the baseline consultation. The
results of the test and management decisions based
on results of the test will be recorded. The time of inocu-
lation will be recorded to ensure that the test is read
within 24 hours. The bacterial growth (i.e. no growth, pure
growth of an organism or mixed growth, and if mixed
growth then presence of predominant growth) will be
recorded. The clinician will record number of colonies,
the colour of colonies for bacterial identification and the
antibiotic resistance of the pure or predominant. The anti-
biotic resistance will only be completed if the growth
is ≥103 cfu/mL. The clinician will then record their man-
agement decision after reading the test. This will include if
they have prescribed any new antibiotic (including name,
dose, and duration). The used POCT will also be photo-
graphed using standardised techniques.
Patient follow-up
Symptom diary
Participants in both trial arms will be followed up on the
course of their illness and their quality of life, using a
two week self-completed daily symptom diary. Partici-
pants will be asked on the day that they see their GP to
complete questions regarding prior UTIs and whether
they had tried to use any products for their symptoms
before going to see their GP. Participants will be asked
to complete The Patient Enablement Instrument which
rates how they are able to cope with and understand
their illness [9,10]. On each of the 14 days since seeing
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and severity of each symptom using a scale of 0 (No
problem) to 6 (Could not be worse) and will also be
asked to record any antibiotic use over the 14 days. On
day 14, participants are asked to complete a section of
the diary which asks if they have seen any healthcare
professionals regarding their UTI in the 14 days after
seeing their GP.
Participants who do not return their diary will be tele-
phoned by the trial team in order to provide a reminder
and enquire whether they need any assistance in return-
ing their diary (new postage-paid envelope for example)
or given the option of giving the information required
over the phone (minimum data set).
Resource use
Resources used in training professionals will be recorded.
For POCT patients, all staff time taken to perform the test
and to contact the patient to report results will be moni-
tored. For all participants, resource use associated with
UTI, including use of antibiotics, non-prescription medi-
cines, hospitalisations, accident and emergency visits, con-
tacts with specialist and time off work will be recorded.
Three-month notes review
The primary care medical records for all participants
will be examined for the three months following recruit-
ment. Data will be recorded onto paper CRFs and entered
onto the online research database. Data collected will
include consultations with both primary and second-
ary care professionals, recurrence of UTI in the three
month period following recruitment and whether any
antibiotics were prescribed. The results of any urine
samples sent for routine laboratory culture will also be
recorded.
Processing of samples by microbiology laboratories
Urine and stool samples obtained from all patients are
analysed in the research laboratories for presence, quantity
and identification of significant Gram-negative bacteria
and antibiotic susceptibility profiles. All laboratories will
be provided with a microbiology manual and standard op-
erating procedures. Data will be recorded onto a standar-
dised spreadsheet provided to each laboratory.
Urine processing
In all sites, urine samples from patients in both trial arms
will be sent to a pre-identified research microbiology
laboratory. Urines will be processed according to the
POETIC microbiology manual provided and local stand-
ard operating procedures, where necessary.
Urine microscopy will be performed using standard
local procedures. Culture will be performed on neat
and diluted urine (10-3, 10-6) spiral-plated onto Columbiablood agar (CBA) (for total colony counts) and UTI
Chromogenic agar (for species specific counts). Enumer-
ation of bacteria will be performed 18-24 hours following
incubation at 35-37°C. Bacterial counts will be summa-
rised into purity of growth (pure, predominant, mixed 2
organisms & >2 mixed organisms).
Pure or predominant organisms from positive urines
will be identified initially with chromogenic agar and
confirmed using MALDI-ToF or other suitable laboratory
methods.
For all UTI positive samples, organisms present
at ≥103 CFU/mL will be stored on cryogenic beads
at -80°C. For all samples a sweep of any growth on the
CBA plate will be stored on cryogenic beads at -80°C.
Susceptibility testing of positive isolate will be perfor-
med following regional research laboratory procedures, in
addition, all positive isolates will also sent to the UK
research laboratory for additional testing.Stool processing
Stool samples will either be tested on the day of arrival at
the laboratory or batched in the fridge until processed.
Dilutions of the stool sample (10-3 and 10-6) will be spiral
plated onto the following antimicrobial screening plates:
CBA, UTI Chromogenic agar, CRE media, ESBL media
and agar supplemented with the antibiotics ciprofloxacin
and gentamycin. Plates will be incubated aerobically for
18-24 hrs at 35 ± 1°C. Only the 3 most predominant
species will be counted. Predominant gram negative or-
ganisms will be identified using basic microbiology or
MALDI-ToF if available.
Isolates will be stored on cryogenic beads at -80°C. For
all samples a sweep of any growth on the CBA plate will
be stored on cryogenic beads at -80°C.
Susceptibility testing of positive isolate will be per-
formed following regional research laboratory procedures
in addition all isolates will also sent to the UK research
laboratory for additional MIC testing.Analysis
Sample size calculation
A total of 614 participants (approximately 154 per net-
work; 307 per arm) are required. We aim to improve ap-
propriate antibiotic prescribing by at least 20% from an
expected level of 55%. However, our sample size calcula-
tion is based on detecting a difference of 15 percentage
points difference from control (i.e. from 55% to 70%).
We need a total sample of 460 (230 for each arm)
patients for final analysis (significance level α = 0.05,
statistical power (1-β) = 0.90) and will recruit 614 pa-
tients to allow for a 25% loss to follow up (which requires
a first urine and also follow-up via diary or telephone
interview).
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The primary outcome will be appropriate antibiotic use
on day 3 (with day 1 being the day that the patient
consulted with their primary care clinician). For women
who are shown to have a UTI, appropriate antibiotic use
on day 3 will be defined as use of an antibiotic for which
the isolated pathogen has been shown to have in vitro
sensitivity (based on laboratory analysis). For women
who do not have a UTI, appropriate antibiotic use on
day 3 will be defined as no antibiotic use on this day.
The analysis of this primary outcome will be intention-
to-treat and will be undertaken utilising a multi-level lo-
gistic regression. Whilst this is an individually randomised
controlled trial we will use multi-level modelling with pa-
tient as the 1st level and practice as the 2nd level, plus we
will test for clustering at the clinician level as the outcome
could be seen as a clinician behavioural measure. Country
will be used as a fixed level covariate at the practice level.
Secondary outcomes will be analysed using multi-level
logistic or linear regression as appropriate, except for
symptoms/recovery (daily symptom score), which will be
modelled over time to allow for the correlation structure
between scores on different days.
This trial is not powered for any sub-group analysis,
and no interim analysis is planned. Some exploratory
sub-group analysis will be done by country, number of
symptoms and recent antibiotic history, using the relevant
variables to form an interaction term with arm in the
model.
Economic evaluation
All resources will be valued using standard methods.
Results will be reported as mean total cost (including
the cost of the POCT for those in the POCT arm) per
unit increase in appropriate antibiotic prescribing. Since
appropriate prescribing may reduce total antibiotic
dispensing and subsequent health care consulting, the
intervention may be shown to dominate best practice
usual care i.e. have lower cost and greater effect, in
which case it will be unambiguously more cost effective.
In the event of non-dominance (higher cost/greater ef-
fect) results will be reported in the form of an incremen-
tal cost effectiveness ratio (ICER) showing the extra cost
per unit improvement in appropriate prescribing.
Uncertainty in any parameters will be assessed through
a series of one way sensitivity analyses. Non-parametric
bootstrapping using 10,000 replications will be applied to
cost and effect data for both groups. A two-dimensional
cost-effectiveness plane will show the uncertainty in
costs and effects through a cost-effectiveness ellipse.
A cost effectiveness acceptability curve will show the
probability of the intervention having an incremental
cost effectiveness ratio below a range of acceptability
thresholds [11].Discussion
The POETIC trial will be the first to evaluate the diagnos-
tic performance cost effectiveness of a POCT (Flexicult™)
for the diagnosis and management of uncomplicated
UTI in primary care. The appropriateness of antibiotic
prescribing will be compared between patients managed
with the aid of Flexicult™ POCT and patients managed
according to guideline informed usual care. The Flexicult™
POCT offers the advantage of quantifying bacterial growth,
organism identification and antibiotic sensitivities within
24 hours at the point of care, and may therefore be a use-
ful adjunct to improving the antimicrobial management of
UTI in primary care. Flexicult™ is already in everyday,
widespread use in Danish primary care, despite it never
have been subject to a clinical trial to determine its cost
effectiveness. Few POCTs have been subjected to rigorous
pragmatic clinical trials that evaluate not only diagnostic
performance but also cost effectiveness using a range of
outcomes including patient orientated measures.
As resources for health care are universally scarce, the
economic evaluation will assess the cost of any benefits
achieved through the use of the POCT. In addition to
the direct costs associated with use of the technology
this will include any savings (or additional costs) which
result from more appropriate diagnosing of UTI. This
will provide additional important information to health
care providers and funders to aid them in making the
most efficient use of their finite resources.
The analyses proposed in POETIC will generate much
needed evidence that should therefore reduce equipoise
about the use of this POCT in managing a common
condition. If shown to be cost effective, the use of this
POCT could benefit individual sufferers and provide evi-
dence for health care authorities to develop evidence
based policies to combat the spread and impact of the
unprecedented rise of infections caused by multi-drug
resistant-gram negative bacteria (MDR-GNB) in Europe.
If shown to be not clinically and cost effective, then that
too will provide evidence to change practice where it is
currently used, and re-focus research efforts on develop-
ing alternative pathways for improving the management
of patients presenting in primary care with symptoms
attributable to UTI.
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